Keywords
Last Name
Institution

David E. Potter

Title
InstitutionMedical University of South Carolina
DepartmentOphthalmology
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Conway SM, Puttick D, Russell S, Potter D, Roitman MF, Chartoff EH. Females are less sensitive than males to the motivational- and dopamine-suppressing effects of kappa opioid receptor activation. Neuropharmacology. 2019 03 01; 146:231-241. PMID: 30528327.
      View in: PubMed
    2. Chartoff EH, Ebner SR, Sparrow A, Potter D, Baker PM, Ragozzino ME, Roitman MF. Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release. Neuropsychopharmacology. 2016 Mar; 41(4):989-1002. PMID: 26239494.
      View in: PubMed
    3. Potter DE, Choudhury M. Ketamine: repurposing and redefining a multifaceted drug. Drug Discov Today. 2014 Dec; 19(12):1848-54. PMID: 25224017.
      View in: PubMed
    4. Van't Veer A, Bechtholt AJ, Onvani S, Potter D, Wang Y, Liu-Chen LY, Sch├╝tz G, Chartoff EH, Rudolph U, Cohen BM, Carlezon WA. Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity. Neuropsychopharmacology. 2013 Jul; 38(8):1585-97. PMID: 23446450.
      View in: PubMed
    5. Husain S, Abdul Y, Potter DE. Non-analgesic effects of opioids: neuroprotection in the retina. Curr Pharm Des. 2012; 18(37):6101-8. PMID: 22747547.
      View in: PubMed
    6. Paes KT, Wang E, Henze K, Vogel P, Read R, Suwanichkul A, Kirkpatrick LL, Potter D, Newhouse MM, Rice DS. Frizzled 4 is required for retinal angiogenesis and maintenance of the blood-retina barrier. Invest Ophthalmol Vis Sci. 2011 Aug 16; 52(9):6452-61. PMID: 21743011.
      View in: PubMed
    7. Husain S, Potter DE, Crosson CE. Opioid receptor-activation: retina protected from ischemic injury. Invest Ophthalmol Vis Sci. 2009 Aug; 50(8):3853-9. PMID: 19324855.
      View in: PubMed
    8. Husain S, Potter DE. The opioidergic system: potential roles and therapeutic indications in the eye. J Ocul Pharmacol Ther. 2008 Apr; 24(2):117-40. PMID: 18355128.
      View in: PubMed
    9. Chartoff EH, Potter D, Damez-Werno D, Cohen BM, Carlezon WA. Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology. 2008 Oct; 33(11):2676-87. PMID: 18185499.
      View in: PubMed
    10. Dortch-Carnes J, Potter DE. Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties. CNS Drug Rev. 2005; 11(2):195-212. PMID: 16007240.
      View in: PubMed
    11. Potter DE, Russell KR, Manhiani M. Bremazocine increases C-type natriuretic peptide levels in aqueous humor and enhances outflow facility. J Pharmacol Exp Ther. 2004 May; 309(2):548-53. PMID: 14742737.
      View in: PubMed
    12. Dortch-Carnes J, Potter DE. Delta-opioid agonist-stimulated inositol phosphate formation in isolated, rabbit iris-ciliary bodies: role of G(i/o) proteins and Gbetagamma-subunits. Exp Eye Res. 2003 Dec; 77(6):647-52. PMID: 14609552.
      View in: PubMed
    13. von Deutsch DA, Abukhalaf IK, Wineski LE, Silvestrov NA, Bayorh MA, Potter DE. Changes in muscle proteins and spermidine content in response to unloading and clenbuterol treatment. Can J Physiol Pharmacol. 2003 Jan; 81(1):28-39. PMID: 12665255.
      View in: PubMed
    14. Chu TC, He Q, Potter DE. Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent. J Ocul Pharmacol Ther. 2002 Dec; 18(6):507-14. PMID: 12537677.
      View in: PubMed
    15. Ogidigben MJ, Potter DE. Pharmacological evidence of a role for prejunctional imidazoline (I(1)) receptors in ocular function. Curr Eye Res. 2002 Nov; 25(5):267-70. PMID: 12658545.
      View in: PubMed
    16. Dortch-Carnes J, Potter DE. Effect of bremazocine, a kappa-opioid receptor agonist, on inositol phosphate formation in isolated iris-ciliary bodies. Pharmacology. 2002 Oct; 66(2):100-6. PMID: 12207117.
      View in: PubMed
    17. Russell KR, Potter DE. Dynorphin modulates ocular hydrodynamics and releases atrial natriuretic peptide via activation of kappa-Opioid receptors. Exp Eye Res. 2002 Sep; 75(3):259-70. PMID: 12384089.
      View in: PubMed
    18. Chu TC, Potter DE. Ocular hypotension induced by electroacupuncture. J Ocul Pharmacol Ther. 2002 Aug; 18(4):293-305. PMID: 12222760.
      View in: PubMed
    19. Abukhalaf IK, von Deutsch DA, Wineski LE, Silvestrov NA, Abera SA, Sahlu SW, Potter DE. Effect of hindlimb suspension and clenbuterol treatment on polyamine levels in skeletal muscle. Pharmacology. 2002 Jul; 65(3):145-54. PMID: 12037378.
      View in: PubMed
    20. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced neuroendocrine changes: increases in ANP and cGMP levels, but suppression of NE, 3H-NE, and cAMP levels in rabbit eyes. Pharmacology. 2002 Jul; 65(3):155-61. PMID: 12037379.
      View in: PubMed
    21. von Deutsch DA, Abukhalaf IK, Wineski LE, Roper RR, Aboul-Enein HY, Paulsen DF, Potter DE. Distribution and muscle-sparing effects of clenbuterol in hindlimb-suspended rats. Pharmacology. 2002 May; 65(1):38-48. PMID: 11901300.
      View in: PubMed
    22. Dortch-Carnes J, Potter DE. Inhibition of cAMP accumulation by kappa-receptor activation in isolated iris-ciliary bodies: role of phosphodiesterase and protein kinase C. J Pharmacol Exp Ther. 2002 May; 301(2):599-604. PMID: 11961062.
      View in: PubMed
    23. Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE, Paulsen DF. Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats. Cells Tissues Organs. 2002; 171(2-3):188-98. PMID: 12097841.
      View in: PubMed
    24. Russell KR, Moore TT, Potter DE. Elevation of atrial natriuretic peptide levels in aqueous humor of the rabbit by kappa opioid receptor agonists. Neuropeptides. 2001 Oct-Dec; 35(5-6):232-7. PMID: 12030807.
      View in: PubMed
    25. Russell KR, Potter DE. Biphasic alterations of cAMP levels and inhibition of norepinephrine release in iris-ciliary body by bremazocine. J Pharmacol Exp Ther. 2001 Sep; 298(3):941-6. PMID: 11504788.
      View in: PubMed
    26. Moore TT, Potter DE. Kappa opioid agonist-induced changes in IOP: correlation with 3H-NE release and cAMP accumulation. Exp Eye Res. 2001 Aug; 73(2):167-78. PMID: 11446767.
      View in: PubMed
    27. Ogidigben MJ, Potter DE. Central imidazoline (I(1)) receptors modulate aqueous hydrodynamics. Curr Eye Res. 2001 May; 22(5):358-66. PMID: 11600937.
      View in: PubMed
    28. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flow: involvement of central and peripheral alpha(2)/I(1) receptors. Exp Eye Res. 2001 Mar; 72(3):331-9. PMID: 11180982.
      View in: PubMed
    29. Zhou L, Thompson WJ, Potter DE. Functional identification of phosphodiesterase activity in human trabecular meshwork cells. J Ocul Pharmacol Ther. 2000 Aug; 16(4):317-22. PMID: 10977127.
      View in: PubMed
    30. von Deutsch DA, Abukhalaf IK, Wineski LE, Aboul-Enein HY, Pitts SA, Parks BA, Oster RA, Paulsen DF, Potter DE. Beta-agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers. Chirality. 2000 Aug; 12(8):637-48. PMID: 10897101.
      View in: PubMed
    31. Chu E, Chu TC, Potter DE. Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: a dopamine(3) receptor agonist. J Pharmacol Exp Ther. 2000 Jun; 293(3):710-6. PMID: 10869368.
      View in: PubMed
    32. Russell KR, Wang DR, Potter DE. Modulation of ocular hydrodynamics and iris function by bremazocine, a kappa opioid receptor agonist. Exp Eye Res. 2000 May; 70(5):675-82. PMID: 10870526.
      View in: PubMed
    33. Abukhalaf IK, von Deutsch DA, Parks BA, Wineski L, Paulsen D, Aboul-Enein HY, Potter DE. Comparative analytical quantitation of clenbuterol in biological matrices using GC-MS and EIA. Biomed Chromatogr. 2000 Apr; 14(2):99-105. PMID: 10694703.
      View in: PubMed
    34. Chu E, Chu TC, Potter DE. Potential sites of action of TNPA: a dopamine-2 receptor agonist. Exp Eye Res. 1999 Dec; 69(6):611-6. PMID: 10620390.
      View in: PubMed
    35. Chu TC, Ogidigben MJ, Potter DE. 8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action. Exp Eye Res. 1999 Aug; 69(2):227-38. PMID: 10433858.
      View in: PubMed
    36. Zhou L, Thompson WJ, Potter DE. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1999 Jul; 40(8):1745-52. PMID: 10393044.
      View in: PubMed
    37. Ogidigben MJ, Chu TC, Potter DE. Peripheral and central effects of naphazoline on ocular hydrodynamics. Involvement of imidazoline receptors, ANP, and Gi proteins. Ann N Y Acad Sci. 1999 Jun 21; 881:388-91. PMID: 10415943.
      View in: PubMed
    38. Chu TC, Han P, Han G, Potter DE. Intraocular pressure lowering by S-allylmercaptocysteine in rabbits. J Ocul Pharmacol Ther. 1999 Feb; 15(1):9-17. PMID: 10048343.
      View in: PubMed
    39. Potter DE, Ogidigben MJ, Chu TC. Lisuride acts at multiple sites to induce ocular hypotension and mydriasis. Pharmacology. 1998 Nov; 57(5):249-60. PMID: 9742290.
      View in: PubMed
    40. Chu TC, Socci RR, Ogidigben MJ, Potter DE. Potential mechanisms of moxonidine-induced ocular hypotension: role of norepinephrine. J Ocul Pharmacol Ther. 1997 Dec; 13(6):489-96. PMID: 9436152.
      View in: PubMed
    41. Chu TC, Socci RR, Potter DE. Moxonidine-induced inhibition of norepinephrine release in monkey and rabbit ciliary bodies: role of cGMP. Pharmacology. 1997 Oct; 55(4):211-6. PMID: 9396081.
      View in: PubMed
    42. Chu TC, Ogidigben MJ, Potter DE. Oxymetazoline: potential mechanisms of inhibitory effects on aqueous humor dynamics. Pharmacology. 1996 Oct; 53(4):259-70. PMID: 8958565.
      View in: PubMed
    43. Chu TC, Burch JL, de Paula Brotto MA, Creazzo TL, Han J, Han GY, Potter DE. Elevation of intracellular Ca2+ concentration in rabbit nonpigmented ciliary epithelial cells by allicin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1996 Sep; 115(1):89-94. PMID: 8983172.
      View in: PubMed
    44. Chu TC, Wong W, Gluchowski C, Hughes BW, Potter DE. Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep; 15(9):943-50. PMID: 8921215.
      View in: PubMed
    45. Wang D, Potter DE. Ocular action of an opioid peptide, DPDPE. J Ocul Pharmacol Ther. 1996; 12(2):131-9. PMID: 8773929.
      View in: PubMed
    46. Campbell WR, Potter DE. Centrally mediated ocular hypotension: potential role of imidazoline receptors. Ann N Y Acad Sci. 1995 Jul 12; 763:463-85. PMID: 7677360.
      View in: PubMed
    47. Campbell WR, Potter DE. The central effects of moxonidine on intraocular pressure and its antagonism by L-659, 066 and L-657, 743 in the rabbit. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Oct; 18(6):1051-61. PMID: 7824759.
      View in: PubMed
    48. Ogidigben M, Chu TC, Potter DE. Ocular actions of moxonidine: a possible role for imidazoline receptors. J Pharmacol Exp Ther. 1994 Jun; 269(3):897-904. PMID: 7912282.
      View in: PubMed
    49. Ogidigben M, Chu TC, Potter DE. Alpha-2 adrenoceptor mediated changes in aqueous dynamics: effect of pertussis toxin. Exp Eye Res. 1994 Jun; 58(6):729-36. PMID: 7925712.
      View in: PubMed
    50. Campbell WR, Potter DE. Potential role of imidazoline (I1) receptors in modulating aqueous humor dynamics. J Ocul Pharmacol. 1994; 10(1):393-402. PMID: 8207342.
      View in: PubMed
    51. Ogidigben M, Chu TC, Potter DE. Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine. J Pharmacol Exp Ther. 1993 Nov; 267(2):822-7. PMID: 7902435.
      View in: PubMed
    52. Potter DE, Ogidigben MJ, Heath AR. Ocular actions of an octahydrobenzo[f]quinoline: Ha117. Eur J Pharmacol. 1993 May 12; 236(1):61-8. PMID: 8100528.
      View in: PubMed
    53. Chu TC, Ogidigben M, Han JC, Potter DE. Allicin-induced hypotension in rabbit eyes. J Ocul Pharmacol. 1993; 9(3):201-9. PMID: 8228529.
      View in: PubMed
    54. Potter D, Chroneos ZC, Baynes JW, Sinclair PR, Gorman N, Liem HH, Muller-Eberhard U, Thorpe SR. In vivo fate of hemopexin and heme-hemopexin complexes in the rat. Arch Biochem Biophys. 1993 Jan; 300(1):98-104. PMID: 8424694.
      View in: PubMed
    55. Ogidigben MJ, Potter DE. Comparative effects of alpha-2 and DA-2 agonists on intraocular pressure in pigmented and nonpigmented rabbits. J Ocul Pharmacol. 1993; 9(3):187-99. PMID: 7901309.
      View in: PubMed
    56. Crosson CE, Heath AR, DeVries GW, Potter DE. Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors. Curr Eye Res. 1992 Oct; 11(10):963-70. PMID: 1360396.
      View in: PubMed
    57. Potter DE, Ogidigben MJ. Medetomidine-induced alterations of intraocular pressure and contraction of the nictitating membrane. Invest Ophthalmol Vis Sci. 1991 Sep; 32(10):2799-805. PMID: 1680113.
      View in: PubMed
    58. Potter DE, Burke JA, Ogidigben MJ. Ocular inhibitory effects of the dopamine DA2 agonist (Ha-118) in cats and rabbits. J Auton Pharmacol. 1990 Jun; 10(3):153-61. PMID: 1974256.
      View in: PubMed
    59. Crosson CE, Burke JA, Chan MF, Potter DE. Prejunctional adrenoceptor activity of N-0437: a relatively selective DA2 dopamine receptor agonist. Eur J Pharmacol. 1990 Mar 27; 178(3):351-5. PMID: 1971223.
      View in: PubMed
    60. Potter DE, Crosson CE, Heath AR, Ogidigben MJ. Review: alpha 2 and DA2 agonists as antiglaucoma agents: comparative pharmacology and clinical potential. J Ocul Pharmacol. 1990; 6(3):251-7. PMID: 1981221.
      View in: PubMed
    61. Crosson CE, Willis JA, Potter DE. Effect of the calcium antagonist, nifedipine, on ischemic retinal dysfunction. J Ocul Pharmacol. 1990; 6(4):293-9. PMID: 2097313.
      View in: PubMed
    62. Potter DE, Crosson CE, Heath AR, Ogidigben MJ. Functional evidence for heterogeneity of ocular alpha 2-adrenoceptors. Proc West Pharmacol Soc. 1990; 33:257-60. PMID: 2177194.
      View in: PubMed
    63. Potter DE, Shumate DJ, Bundgaard H, Lee VH. Ocular and cardiac beta-antagonism by timolol prodrugs, timolol and levobunolol. Curr Eye Res. 1988 Aug; 7(8):755-9. PMID: 2903009.
      View in: PubMed
    64. Potter DE, Burke JA. LY141865: a relatively selective DA2 agonist with complex ocular activity. J Ocul Pharmacol. 1988; 4(1):19-28. PMID: 2902177.
      View in: PubMed
    65. Crosson CE, Burke JA, Chan MF, Potter DE. Ocular effects of a N,N-disubstituted 5-OH aminotetralin (N-0437): evidence for a dual mechanism of action. Curr Eye Res. 1987 Nov; 6(11):1319-26. PMID: 3427980.
      View in: PubMed
    66. Burke JA, Potter DE. Aporphine derivatives affect ocular function in diverse ways. Curr Eye Res. 1987 Oct; 6(10):1227-36. PMID: 3677783.
      View in: PubMed
    67. Potter DE, Shumate DJ. Cianergoline lowers intraocular pressure in rabbits and monkeys and inhibits contraction of the cat nictitans by suppressing sympathetic neuronal function. J Ocul Pharmacol. 1987; 3(4):309-21. PMID: 3503920.
      View in: PubMed
    68. Burke JA, Potter DE. Ocular effects of a relatively selective alpha 2 agonist (UK-14, 304-18) in cats, rabbits and monkeys. Curr Eye Res. 1986 Sep; 5(9):665-76. PMID: 2876846.
      View in: PubMed
    69. Phipps TL, Potter DE, Rowland JM. Effects of ibuterol, a beta-2 adrenergic prodrug, on intraocular pressure. J Ocul Pharmacol. 1986; 2(3):225-37. PMID: 3503109.
      View in: PubMed
    70. Burke JA, Potter DE. The ocular effects of xylazine in rabbits, cats, and monkeys. J Ocul Pharmacol. 1986; 2(1):9-21. PMID: 3503099.
      View in: PubMed
    71. Potter DE, Burke JA, Temple JR. Forskolin suppresses sympathetic neuron function and causes ocular hypotension. Curr Eye Res. 1985 Feb; 4(2):87-96. PMID: 4039243.
      View in: PubMed
    72. Chang FW, Burke JA, Potter DE. Mechanism of the ocular hypotensive action of ketanserin. J Ocul Pharmacol. 1985; 1(2):137-47. PMID: 3880071.
      View in: PubMed
    73. Potter DE, Burke JA. An in vivo model for dissociating alpha 2-and DA2-adrenoceptor activity in an ocular adnexa: utility of the cat nictitating membrane preparation. Curr Eye Res. 1984 Nov; 3(11):1289-98. PMID: 6150810.
      View in: PubMed
    74. Burke JA, Chang FW, Potter DE. Effects of aminotetralins on intraocular pressure and pupillary function in rabbits. J Auton Pharmacol. 1984 Sep; 4(3):185-92. PMID: 6490680.
      View in: PubMed
    75. Potter DE, Burke JA, Chang FW. Alteration in ocular function induced by phenylethylamine analogs of dopamine. Curr Eye Res. 1984 Jun; 3(6):851-9. PMID: 6329603.
      View in: PubMed
    76. Potter DE, Burke JA, Chang FW. Ocular hypotensive action of ergoline derivatives in rabbits: effects of sympathectomy and domperidone pretreatment. Curr Eye Res. 1984 Feb; 3(2):307-14. PMID: 6142811.
      View in: PubMed
    77. Potter DE, Burke JA. Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys. Curr Eye Res. 1982-1983; 2(5):281-8. PMID: 6131794.
      View in: PubMed
    78. Potter DE, Nicholson HT, Rowland JM. Ocular hypertensive response to beta-adrenoceptor agonists. Curr Eye Res. 1982-1983; 2(10):711-9. PMID: 6137324.
      View in: PubMed
    79. Potter DE, Morris JW, Rowland JM. Effects of ethanol, acetaldehyde and acetate on insulin release from perifused pancreatic islets. Pharmacology. 1982; 24(5):314-20. PMID: 7048345.
      View in: PubMed
    80. Potter DE. Adrenergic pharmacology of aqueous humor dynamics. Pharmacol Rev. 1981 Sep; 33(3):133-53. PMID: 7323134.
      View in: PubMed
    81. Rowland JM, Potter DE, Reiter RJ. Circadian rhythm in intraocular pressure: a rabbit model. Curr Eye Res. 1981; 1(3):169-73. PMID: 7297102.
      View in: PubMed
    82. Rowland JM, Potter DE. Steric structure activity relationships of various adrenergic agonists: ocular and systemic effects. Curr Eye Res. 1981; 1(1):25-35. PMID: 6117417.
      View in: PubMed
    83. Potter DE, Rowland JM. Adrenergic drugs and intraocular pressure. Gen Pharmacol. 1981; 12(1):1-13. PMID: 7250663.
      View in: PubMed
    84. Rowland JM, Potter DE, Lombardini JB. Taurine concentrations in the aqueous humor and plasma of anesthetized rabbits. Experientia. 1980 Aug 15; 36(8):980-1. PMID: 7439337.
      View in: PubMed
    85. Rowland JM, Potter DE. The effects of topical prazosin on normal and elevated intraocular pressure and blood pressure in rabbits. Eur J Pharmacol. 1980 Jun 27; 64(4):361-3. PMID: 7389829.
      View in: PubMed
    86. Rowland JM, Potter DE. Adrenergic drugs and intraocular pressure: suppression of ocular hypertension induced by water loading. Exp Eye Res. 1980 Jan; 30(1):93-104. PMID: 6102526.
      View in: PubMed
    87. Potter DE, Chin CA, Rowland JM. Acute pretreatment with pyrazole and ethanol: effects on glucose-induced changes in insulin and glucagon. Pharmacology. 1980; 20(4):203-10. PMID: 6992153.
      View in: PubMed
    88. Woodson LC, Potter DE. The influence of endogenous glucagon release on hyperglycemic responses to catecholamines in normal fed and diabetic rats. J Pharmacol Exp Ther. 1979 Sep; 210(3):458-64. PMID: 480194.
      View in: PubMed
    89. Rowland JM, Potter DE. Effects of adrenergic drugs on aqueous cAMP and cGMP and intraocular pressure. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1979; 212(2):65-75. PMID: 44821.
      View in: PubMed
    90. Potter DE, Rowland JM. Adrenergic drugs and intraocular pressure: effects of selective beta-adrenergic agonists. Exp Eye Res. 1978 Dec; 27(6):615-25. PMID: 33056.
      View in: PubMed
    91. Woodson LC, Kempen RR, Bee DE, Potter DE. Role of glucagon in the hyperglycemic response to catecholamines in fasted baboons. Pharmacology. 1978; 17(4):221-6. PMID: 99754.
      View in: PubMed
    92. Potter DE, Wilson LM, Ellis S. Changes in plasma glucose and insulin levels induced by adrenergic agents in normal and alloxan-diabetic rats. Proc Soc Exp Biol Med. 1977 Mar; 154(3):337-40. PMID: 851459.
      View in: PubMed
    93. Moratinos J, Ellis S, Potter DE. Catecholamine-induced changes in plasma glucose and insulin levels in the unanesthetized rabbit. Pharmacology. 1977; 15(5):407-14. PMID: 918144.
      View in: PubMed
    94. Potter DE, Ellis S. Isoproterenol- and epinephrine-induced changes in blood glucose and tissue glycogen levels in normal and diabetic rats: the influence of alteration in endogenous insulin levels and state of nourishment. J Pharmacol Exp Ther. 1975 May; 193(2):576-84. PMID: 1142106.
      View in: PubMed
    95. Potter DE, Walaszek EJ. Modification of polypeptide activity by cysteine analogs: structure-activity relationship. Pharmacology. 1971; 5(6):359-71. PMID: 5119544.
      View in: PubMed
    96. MCCARTHY DA, POTTER DE, NICOLAIDES ED. AN IN VIVO ESTIMATION OF THE POTENCIES AND HALF-LIVES OF SYNTHETIC BRADYKININ AND KALLIDIN. J Pharmacol Exp Ther. 1965 Apr; 148:117-22. PMID: 14279175.
      View in: PubMed
    Potter's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description